TELA Bio's New CEO Starts With a $39 Million Loss and a Trust Test

TELA Bio's leadership change lands right before earnings

TELA Bio has swapped CEOs effective August 3, 2026: Antony Koblish was terminated as CEO and resigned from the board, and Heather Getz was appointed CEO and director. The handoff comes just before the Q2 earnings call on August 10, making this less of a routine succession story than a near-term operating test.

For investors, the immediate question is not Getz's background itself, but whether TELA can show two things at once: continued commercial traction and a more controlled cost base. In 2025, the company generated $80.28 million in revenue but also reported a $38.83 million net loss.

Getz's strengths fit an execution-focused next phase

Getz brings more than 25 years in healthcare and medical-device companies, including experience leading acquisitions and integrations across 40-plus companies and securing more than $1 billion in financing. That background matters if the next phase is about sales discipline, cost control, and making sure commercial spending earns a return.

Still, the biography only matters if it changes day-to-day execution. A new CEO this close to earnings can help sharpen accountability, but it does not by itself prove better adoption, better margins, or slower cash burn.

Commercial traction, not management narrative, will decide the stock

That is why the Q2 earnings call on August 10 matters more than the press release. TELA is already commercial-stage, with $80.28 million in 2025 revenue and a nearly $39 million loss. The core opportunity is straightforward: if OviTex products continue gaining use in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery, the company can start to build credibility around execution rather than rely on the leadership-change story.

The board refresh supports the change, but it does not prove it

Earlier this year, TELA said it was adding four new highly accomplished executives to support commercial growth and operational excellence. That can help. A refreshed board can push for better sales discipline, coverage, and spending discipline.

But a board reset is still only an enabler. The real proof will show up in adoption, revenue durability, and cost control.

What investors should watch on the earnings call

Investors should listen for clearer answers on three points:

• Revenue quality: Is OviTex traction broadening across indications, or is growth still resting on a narrow set of users or procedures?
• Cost control: Is the company making measurable progress in managing spending relative to revenue?
• Execution credibility: Does management connect the leadership change to specific operating improvements, or stop at the announcement itself?

If those answers improve, the leadership change will look more meaningful. If not, the market is likely to treat it as cosmetic.